ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PODD / forecast
GMED (69) BAX (50) PEN (57) SOLV (44) ⌘ Pro Terminal →

Insulet Corporation (PODD) 12-Month Stock Forecast & Price Target Cone

$153.61 +2.63% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $154.71

Insulet Corporation (PODD) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (71.6% gross margin, 20% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $10.38B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PODD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PODD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Insulet Corporation (NASDAQ: PODD) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $153.61 (+2.63% 1D, market cap $10.38B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, PODD ranks #58 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PODD compare to GMED and BAX in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), PODD carries a Roarable B (72/100 RQD), trailing P/E of 42.8x, gross margin of 71.6%, and ROIC of 20.4%. By comparison, GMED (Globus Medical Inc.) holds a C+ grade (69/100 RQD, P/E 20.7x, ROIC 8.7%, cap $10.48B) and BAX (Baxter International Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -2.4%, cap $11.90B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while PODD leads on capital efficiency (20.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PODD?
▼

Per PODD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001145197), Insulet Corporation generated $2.71B in revenue (+30.7% YoY), $247.1M in net income, and $377.7M in free cash flow against $3.19B in total assets and $753.8M in total debt. Key quantitative strengths: Strong cash generator (71.6% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $154.70 (+0.71%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 13.9% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B
025507510072
2-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw B · Rk C+
Cash (19)Whales (10)SEC (18)Macro (9)CEO (16)
Each axis scored 0–20
12M PRICE TARGET CONE+6.3% Base Target
$373 Bull$163 Base$126 Bear
📬 FREE PODD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PODD)Realized 20D OHLCV Swing Band: ±6.1%
Deterministic 5-Pillar Attribution (72/100 Composite)
🔍 WHY PODD SCORES 72/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (26% of score)

SEC XBRL FY 2025 (10-K): 13.9% FCF Margin ($377.7M FCF) & 71.6% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (25% of score)

Altman Z-Score 5.72 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Macro Regime Fit9/20 pts (-11 pt drag)

Macro rate sensitivity & RSI-14 (59.3) create a -11 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
64
Grade C+$133.93+6% Next Q
Q2 (-2Q)
67
Grade B-$141.90+5% Next Q
Q3 (-1Q)
69
Grade B-$148.93+3.1% Next Q
Current
72
Grade B$153.61+7% Hist 90D α
Trajectory: C+ (64) → B (72)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PODD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 72/100 (B) score, PODD faces multiple-compression risk if 42.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Priced at 43x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($141.27) or 200D SMA ($176.78) invalidates the momentum regime and cuts Target Base ($163.29) toward Bear Floor ($125.96).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PODD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PODD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 72%NO 28%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your PODD Position Size: $10,000

Shares at $153.61: 65.1 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $125.96
$8,200
$-1,800 (-18.0%)
12M Consensus BaseTarget $163.29
$10,630
+$630 (+6.3%)
12M Bull Case BreakoutTarget $372.62
$24,258
+$14,258 (+142.6%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (34 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 23● Hold: 9● Sell: 2
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskOUTPERFORM$17074%A
Goldman SachsSector Coverage LeadBUY$35069%B
JP MorganUS Large-Cap ResearchHOLD$14558%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (PODD Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PODD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -10.37%⚡ TESTING RESISTANCE
2026-11-03O $152.5H $153.6L $149.7C $153.6VOL 1.09M
RES: $154.9SUP: $128.9SMA50: $141.3SMA200: $176.8
$292.3$247.4$202.4$157.4$112.4RES $154.9SUP $128.9$153.62026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PODD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PODD Butterfly Map → + Track PODD →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
32.2%/yr Implied 5Y Growth

vs. +30.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PODD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PODD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PODD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PODD)

Health Care Rank #58 of 1015 ⚔️ GMED vs PODD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PODD vs. GMED, BAX, PEN, SOLV)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Insulet Corporation (PODD) ranks #58 by composite RQD confidence (72/100, grade B) and #104 by equity capitalization ($10.38B). Within this direct 5-issuer industry benchmark cohort, SOLV leads on earnings valuation at 9.1x trailing P/E, while PODD leads on capital efficiency and profitability with 20.4% ROIC and 71.6% gross margin. PODD currently leads its immediate peer cohort in composite quantitative strength at 72/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PODD ACTIVE
Insulet Corporation
B 72/100 42.8x 71.6% 20.4% +2.63% $10.38B Benchmark Subject
GMED
Globus Medical Inc.
C+ 69/100 20.7x 67.4% 8.7% +1.81% $10.48B /gmed-vs-podd →
BAX
Baxter International Inc.
D 50/100 — 30.1% -2.4% +5.30% $11.90B /bax-vs-podd →
PEN
Penumbra Inc.
D+ 57/100 71.4x 67.1% 10.6% +0.75% $12.57B /pen-vs-podd →
SOLV
Solventum Corporation
D 44/100 9.1x 53.5% 18.7% +4.21% $13.84B /solv-vs-podd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001145197 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Insulet Corporation (PODD) reported GAAP revenue of $2.71B (+30.7% vs. FY2024 revenue of $2.07B , and +59.6% cumulative change since FY2023) , GAAP net income of $247.1M, operating cash flow of $569.3M, and free cash flow of $377.7M (+23.7% YoY). On the balance sheet, PODD closed FY2025 with $3.19B in total assets against $753.8M in total debt (Altman Z-Score: 5.72, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.71B $247.1M $569.3M $377.7M $3.19B $753.8M
FY2024 (FY) 2024-12-31 $2.07B $418.3M $430.2M $305.3M $3.09B $844.2M
FY2023 (FY) 2023-12-31 $1.70B $206.3M $145.7M $69.3M $5.82B $1.36B

3. PODD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PODD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Insulet Corporation (NASDAQ: PODD) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $153.61 (+2.63% 1D, market cap $10.38B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, PODD ranks #58 in composite RQD confidence.

How does PODD compare to GMED and BAX in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), PODD carries a Roarable B (72/100 RQD), trailing P/E of 42.8x, gross margin of 71.6%, and ROIC of 20.4%. By comparison, GMED (Globus Medical Inc.) holds a C+ grade (69/100 RQD, P/E 20.7x, ROIC 8.7%, cap $10.48B) and BAX (Baxter International Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -2.4%, cap $11.90B). Among the 5-stock peer group, SOLV leads on earnings multiple (9.1x) while PODD leads on capital efficiency (20.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PODD?

Per PODD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001145197), Insulet Corporation generated $2.71B in revenue (+30.7% YoY), $247.1M in net income, and $377.7M in free cash flow against $3.19B in total assets and $753.8M in total debt. Key quantitative strengths: Strong cash generator (71.6% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PODD trading relative to its 50-day, 200-day, and 52-week technical levels?

PODD last traded at $153.61 (+2.63% on volume of 1,772,797 shares), positioning the stock +8.74% above its 50-day simple moving average ($141.27) and -13.11% below its 200-day simple moving average ($176.78). Across its 52-week range of $126.40 to $354.88, PODD sits at the 11.9% percentile with a 14-day RSI of 59.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.1% ($144.24 to $162.98).

Direct Sub-Reports: PODD RQD Cockpit PODD 12M Forecast PODD Earnings & Move PODD Dividends & DRIP PODD Insiders & 13F PODD Whale Options PODD Profit Sankey PODD News & Why
ROARABLE RATING BRIEF • RQD 72/100 (B) ✓ SEC XBRL & RQD VERIFIED

PODD — Insulet Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Insulet Corporation (PODD) earns a live Roarable RQD composite score of 72/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $153.61 (+2.63% 1D, market capitalization $10.38B).

  • Fundamental Cash Engine (19/20): Anchored by return on invested capital (ROIC) of 20.4%, gross margin of 71.6%, operating margin of 17.5%, and free cash flow yield of 3.57%.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (16/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (18/20): Incorporates a 0.99x equity beta, Altman Z-Score of 5.72, Piotroski F-Score of 8/9, and Debt/Equity of 0.46x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Insulet Corporation is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. — for specific products, customers, or revenue-generation detail. The source data reports gross margin of 71.6%, operating margin of 17.5%, and net margin of 9.1% per the market data section.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Insulet Corporation (PODD) reported $2.71B in annual revenue (up from $2.07B in FY2024, +30.7% YoY) and $247.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.70B revenue, $206.3M net income) through FY2025, PODD scaled operating cash flow to $569.3M and free cash flow to $377.7M, backed by $3.19B in total assets against $753.8M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B • RQD 72/100): Strong cash generator (71.6% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 19/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $126.40 – $354.88 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 42.8x trailing P/E and 17.1x EV/EBITDA against 17.5% operating margins and a 0.99x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Medical/Dental Instruments (Health Care), PODD carries a macro regime beta of 0.99 and gross margin of 71.6%.

  • Key Question #1: Can PODD sustain or expand its 17.5% operating margin and 20.4% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $2.71B and free cash flow of $377.7M, how will capital allocation balance growth reinvestment against $753.8M in total debt?
  • Key Question #3: How sensitive is PODD's 36.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.99x)?

PODD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Insulet Corporation (PODD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PODD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PODD Bull vs. Bear Conversation Board — What's Your Call at $153.61?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PODD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PODD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $188.60 (+26.0%)
📌 Pinned Debate

Per the RQD cash-engine pillar, ROIC of 20.4% and a strong forensic balance sheet (Altman Z 5.72; Piotroski F 8/9) support the rating.

Long PODD at $149.68 targeting $188.60. Per the RQD cash-engine pillar, ROIC of 20.4% and a strong forensic balance sheet (Altman Z 5.72; Piotroski F 8/9) support the rating.. Institutional whale score is 10/20 and the risk/reward vs. the $126.40 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader 🐂 BULL

@BearTrap_Alert Shorting a 10/20 institutional whale-flow stock at $149.68 is dangerous when funds are rotating into Health Care.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $118.25 (-21.0%)
Spot @ $149.68

Per the market data, trailing P/E of 42.8 and a 52-week range of $126.4 to $354.88 point to high valuation sensitivity, with macro regi

Sitting on the sidelines or leaning short PODD above $149.68. Per the market data, trailing P/E of 42.8 and a 52-week range of $126.4 to $354.88 point to high valuation sensitivity, with macro regime fit at 9/20.. Until Fundamental Cash Engine (19/20) and FCF yield (3.57%) inflect higher, upside is capped near $354.88.

LIVE TAPE